Neurosterix, a spinout of Swiss biotech Addex Therapeutics, has raised $105 million (about €94 million) to advance its lead schizophrenia drug into Phase 2 clinical development. The Boston- and Geneva-based company has also recruited three veterans of Karuna Therapeutics, including Cobenfy inventor Andrew Miller.
Amsterdam-based VectorY Therapeutics has secured €74.5 million ($83.5 million) in new financing to advance its lead gene therapy candidate for amyotrophic lateral sclerosis (ALS) and expand its pipeline of treatments for neurodegenerative diseases. The funding includes a €30 million convertible loan from the European Investment Bank (EIB).
London-based Kesmalea Therapeutics has raised $60 million (about €53.5 million) in a Series A-2 financing and rebranded as Oyster Therapeutics. The funding will support the development of an oral, brain-penetrant protein degrader targeting tau, a protein implicated in Alzheimer’s disease and other neurodegenerative disorders.
Cambridge-based T-Therapeutics has raised $133 million (€118 million) in an oversubscribed Series B financing to advance two experimental T-cell engager therapies for cancer and autoimmune diseases into clinical trials. The round brings the University of Cambridge spinout’s total Series A and B funding to $224 million.
Portugal-based Exogenus Therapeutics will lead a five-year, €13 million Horizon Europe project to advance its osteoarthritis candidate EXO-101 into clinical testing.
Switzerland-based Atlas Bio has emerged from stealth with $12.5 million in funding to develop AI simulations that predict drug responses, with the ambition of replacing parts of clinical development and animal testing.
Swiss biotech Nouscom has raised €120 million in an oversubscribed Series D financing to advance NOUS-209, an experimental cancer vaccine designed to prevent tumors in people with Lynch syndrome, into a global registration-enabling clinical trial. Alongside the financing, the company has released new long-term clinical data showing encouraging signs of cancer prevention.
U.K. microbiome company Microbiotica has raised £36 million (€43 million), the first close of a Series C round led by the British Business Bank, to take its ulcerative colitis drug MB310 into Phase 2.
Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule pipeline in endocrinology and immunology, including a potential treatment for congenital adrenal hyperplasia that will compete with drugs developed by Vertex and Neurocrine Biosciences.
Dutch biotech RougeTx has launched with a $58 million (€52 million) series A to take its lead drug RTX-001 toward first-in-human testing in hereditary hemorrhagic telangiectasia (HHT). The round was co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with the European Investment Bank (EIB) participating through Angelini’s Aurea co-investment vehicle.